Moreover, this study highlighted differential dependencies of AML cells on NDUFA6, SDHA, CYB5A, SLC25A12, ETFB, and CPT1A which could rationally guide personalized therapy of AML patients. The gene discussed is CPT1A; the disease is acute myeloid leukemia.